‘When I started in IR, I told my wife I would stay in the job for five years – no more,’ says Dr Karl Mahler, who not only stuck with the profession but led the investor relations program at pharmaceuticals giant Roche for 20 years before (semi) retiring this year. During that time, he has won multiple IR awards for his work, pioneered ESG reporting and nurtured a host of IR talent, with former members of his team going on to run IR programs everywhere from AstraZeneca to Twitter.
Like many, Mahler moved into IR after simply finding that his particular . . .
Log in FOR FREE to access this content
Log in or create your free My IR – Essentials account to:
- Access 50+ deep dives and best practice reports
- View 100+ news analyses and our exclusive CFO series
- Instantly benchmark your IR program with our new tool
- Save favorites and get tailored content delivered to your dashboard
- 10% off all IR forums!
Join now to make a real impact in your organization.
